Shane Rowan is a Cardiology physician. OpenAlex indexes 16 publications with 620 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1760 E Ken Pratt Blvd Ste 205
Longmont, CO 805045311
Telephone
720-718-8180Provider last certified this registry record 14 Aug 2025.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20257 payments
- Boston Scientific CorporationProgram year20259 payments
- Impulse Dynamics (USA) Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
76.1%Beta blocker22.2%Metoprolol Succinate38%Metoprolol Tartrate28%Carvedilol17%Sotalol12%Nebivolol Hcl6%Part D<11 patientsStatin10.3%Atorvastatin Calcium80%Rosuvastatin Calcium20%Part D≥47 patients+ 10 more classes in this area
Blood & clotting
22.3%Factor Xa inhibitor15.4%Eliquis69%Xarelto31%Part D≥57 patientsVitamin K antagonist3.6%Warfarin Sodium100%Part D≥18 patients+ 2 more classes in this area
Metabolism & gastrointestinal
1.7%Potassium supplement1.7%Potassium Chloride100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of Voltage Mapping to Guide Whether to Perform Ablation of the Posterior Wall in Patients With Persistent Atrial Fibrillation
Journal of Cardiovascular Electrophysiology
2015 - Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation
Journal of the American College of Cardiology
2012 - Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation
Journal of the American College of Cardiology
2012 - A Common β1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Therapy in Atrial Fibrillation
Journal of the American College of Cardiology
2011
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”